Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.

Shukui Qin,Feng Bi,Shanzhi Gu,Yuxian Bai,Zhendong Chen,Zishu Wang,Jieer Ying,Yinying Lu,Zhiqiang Meng,Hongming Pan,Ping Yang,Helong Zhang,Xi Chen,Aibing Xu,Chengxu Cui,Bo Zhu,Jian Wu,Xiaoli Xin,Jufeng Wang,Jinlu Shan,Junhui Chen,Zhendong Zheng,Li Xu,Xiaoyu Wen,Zhenyu You,Zhenggang Ren,Xiufeng Liu,Meng Qiu,Liqing Wu,Feng Chen

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.

2021

PURPOSEDonafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy...

Keywords:

open label
Internal medicine
first line treatment
multikinase inhibitor
Sorafenib
Medicine
Hepatocellular carcinoma
PHASE II/III TRIAL
Metastatic hepatocellular carcinoma
Tolerability
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations